The ruling removes near-term downside risk to royalty rates and strengthens AnaptysBio’s negotiating and litigation position ahead of the July 2026 trial. Traders should monitor Jemperli sales trends and trial developments as catalysts for valuation re-rating, especially if reversion rights gain legal traction.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 24 $58.88entry
- T+1 · 7mo ago +13.09%α +12.93% · $66.59
- T+5 · 7mo ago +11.63%α +10.72% · $65.73
- T+20 · 6mo ago +2.60%α −1.43% · $60.41
- T+60 · 4mo ago −8.70%α −13.78% · $53.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the Delaware Chancery Court dismissing Tesaro’s claim of anticipatory breach and upholding the current royalty structure for Jemperli. The decision preserves AnaptysBio’s right to receive tiered royalties (up to 25%) and sets the stage for a July 2026 trial on Anaptys’ claims of material breach and reversion rights.
Key Facts
- Delaware Chancery Court dismissed Tesaro’s anticipatory breach claim against AnaptysBio.
- Court rejected Tesaro’s request to reduce royalty rates on Jemperli sales.
- Current royalty structure upheld: 8% below $1B, 12% between $1B–$1.5B, 20% between $1.5B–$2.5B, and 25% above $2.5B in annual net sales.
- Trial on AnaptysBio’s claims, including right to reversion of Jemperli, scheduled for July 14–17, 2026.
- Anaptys claims Tesaro breached exclusivity, diligence, and notice obligations under the Collaboration Agreement.
Financial Impact
Preserves potential royalty stream worth hundreds of millions of dollars; Jemperli sales were $1.2B in 2025 (implied from royalty tiers and public data). At current trajectory, Anaptys could receive ~$144M annually (12% of $1.2B), with upside to 20–25% as sales grow.
Risk Factors
- Final outcome of trial in July 2026 remains uncertain; reversion of Jemperli is not guaranteed.
- GSK/Tesaro may appeal or pursue further legal action.
- Royalty revenue dependent on continued commercial performance of Jemperli.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281057 |
Track record
28 reports on ANAB
9 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 12 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers